{
  "id": 15259960,
  "title": "AI Drug Discovery in 2026: How Artificial Intelligence Is Changing Medicine",
  "url": "https://urgent.news/2026/10/17/ai-drug-discovery-in-2026-how-artificial-intelligence-is-changing",
  "topic": "ai",
  "section": "AI",
  "published": "2026-10-17T19:00:27.000Z",
  "source": {
    "name": "Dev.to",
    "slug": "dev-to",
    "url": "https://dev.to/the_daily_flare/ai-drug-discovery-in-2026-how-artificial-intelligence-is-changing-medicine-59kd"
  },
  "original_language": "en",
  "account": "AI Drug Discovery in 2026: How Artificial Intelligence Is Changing Medicine\n\nThe transformative potential of artificial intelligence in drug discovery has gained significant recognition in recent years. In 2024, the Nobel Prize in Chemistry was awarded to Demis Hassabis and John Jumper of Google DeepMind, alongside David Baker of the University of Washington for their work on AlphaFold. AlphaFold's groundbreaking achievement was predicting protein structures with unprecedented accuracy, revolutionizing the way scientists understand and manipulate biological molecules.\n\nBy 2026, AI-designed drugs have entered human trials, with notable examples including Insilico Medicine's rentosertib (Phase III) and Isomorphic Labs' oncology candidates. The traditional drug discovery pipeline, which involved manually screening thousands of compounds and testing them in cells and animals, has been significantly altered by AI. Machine learning models now predict protein folding, design novel molecules from scratch, and identify patient populations most likely to respond to specific treatments.\n\nAlphaFold's 2024 Nobel Prize served as the foundation for modern AI drug discovery. The protein structure prediction tool solved a major challenge in biology, allowing researchers to access over 200 million predicted protein structures. This wealth of data has enabled more efficient and accurate drug design. AlphaFold 3 further expanded the field by predicting interactions between proteins, DNA, RNA, and small molecules, bridging the gap between predicting molecular structures and designing new ones.\n\nCompanies like Isomorphic Labs and Insilico Medicine have embraced AI drug discovery, with Isomorphic Labs developing the Isomorphic Labs Drug Design Engine (IsoDDE). This engine has doubled AlphaFold 3's performance on protein-ligand structure prediction and predicts binding affinities more accurately than traditional methods. Isomorphic Labs has focused its efforts on oncology and immunology, with AI-designed candidates entering first-in-human trials. Insilico Medicine also made history by designing its first AI-generated drug candidate, rentosertib, which is currently in Phase IIa trials for idiopathic pulmonary fibrosis.",
  "summary": "Originally published on The Daily Flare . KEY TAKEAWAYS AlphaFold's 2024 Nobel Prize validated AI's central role in biology, with over 200 million protein structures freely available to researchers. AI-designed drugs are now in human trials, including Insilico Medicine's rentosertib (Phase III) and Isomorphic Labs' oncology candidates. Bringing a drug to market costs about $2.6 billion with only…",
  "key_points": [
    "AI drug discovery awarded Nobel Prize in Chemistry in 2024",
    "AI-designed drugs enter human trials by 2026",
    "AlphaFold predicts protein structures and interactions"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}